GS
ADMA icon

GTS Securities’s ADMA Biologics ADMA Stock Holding History

GTS Securities’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91.5K Buy
+10,153
New +$160K ﹤0.01% 1428
2023
Q4 		– Sell
-10,571
Closed -$37.8K – 3997
2023
Q3 		$37.8K Buy
+10,571
New +$40.7K ﹤0.01% 3742

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

GTS Securities's ADMA Position: Q1 2026 in Review

GTS Securities opened a new position in ADMA Biologics (ADMA) in Q1 2026: 10,153 shares worth $91.5K. The stake represents ﹤0.01% of the portfolio and ranks #1428 among its holdings. This is a return to the name: GTS Securities previously reported a position in ADMA as recently as Q3 2023.

GTS Securities first reported a position in ADMA in Q3 2023 and has held it in 2 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • GTS Securities held 10,153 shares of ADMA Biologics worth $91.5K as of Q1 2026.
  • ADMA Biologics was a new GTS Securities position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1428 holding.
  • GTS Securities first reported a position in ADMA Biologics in Q3 2023 and has held it in 2 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.